← Patent-cliff monitor small molecule MOUNJARO TIRZEPATIDE
Loss of exclusivity December 2041 latest FDA-listed patent expiry
Company ELI LILLY AND CO
Drug detail Brand name MOUNJARO Active ingredient TIRZEPATIDE Strength 10MG/2.4ML (4.17MG/ML) Dosage form SOLUTION Route SUBCUTANEOUS Modality Small molecule FDA approval January 2026 Marketing status RX
Listed patents Patent Expires Type 12295987 December 2041 use U-4192 12343382 July 2039 use U-4230 12616740 July 2039 use U-4502 9474780 May 2036 substance, product
Regulatory exclusivity Code Expires NPP December 2028 NCE May 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.